Laird Norton Wetherby Wealth Management LLC Sells 1,595 Shares of Humana Inc. (NYSE:HUM)

Laird Norton Wetherby Wealth Management LLC lessened its stake in shares of Humana Inc. (NYSE:HUM - Free Report) by 36.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,812 shares of the insurance provider's stock after selling 1,595 shares during the quarter. Laird Norton Wetherby Wealth Management LLC's holdings in Humana were worth $713,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of HUM. Wealth Enhancement Advisory Services LLC increased its holdings in Humana by 1.6% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 8,848 shares of the insurance provider's stock valued at $2,245,000 after purchasing an additional 138 shares in the last quarter. Czech National Bank increased its stake in shares of Humana by 6.4% in the 4th quarter. Czech National Bank now owns 26,108 shares of the insurance provider's stock valued at $6,624,000 after buying an additional 1,581 shares during the period. 180 Wealth Advisors LLC increased its stake in shares of Humana by 15.6% in the 4th quarter. 180 Wealth Advisors LLC now owns 1,291 shares of the insurance provider's stock valued at $327,000 after buying an additional 174 shares during the period. Assenagon Asset Management S.A. increased its stake in shares of Humana by 21.5% in the 4th quarter. Assenagon Asset Management S.A. now owns 4,969 shares of the insurance provider's stock valued at $1,261,000 after buying an additional 879 shares during the period. Finally, Park Avenue Securities LLC increased its stake in shares of Humana by 77.8% in the 4th quarter. Park Avenue Securities LLC now owns 8,635 shares of the insurance provider's stock valued at $2,191,000 after buying an additional 3,778 shares during the period. 92.38% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on HUM. Oppenheimer raised their price target on Humana from $300.00 to $310.00 and gave the stock an "outperform" rating in a research report on Thursday, May 1st. Robert W. Baird raised their price target on Humana from $270.00 to $300.00 and gave the stock a "neutral" rating in a research report on Tuesday, April 15th. JPMorgan Chase & Co. reduced their target price on Humana from $257.00 to $256.00 and set a "neutral" rating on the stock in a report on Tuesday, February 18th. Guggenheim began coverage on Humana in a report on Wednesday, April 9th. They set a "buy" rating and a $326.00 target price on the stock. Finally, Royal Bank of Canada restated an "outperform" rating and issued a $283.00 price target on shares of Humana in a report on Wednesday, February 12th. Seventeen equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $286.81.

Humana Stock Up 4.4%

Shares of NYSE:HUM traded up $9.95 during midday trading on Friday, reaching $237.42. The company had a trading volume of 2,548,740 shares, compared to its average volume of 1,767,307. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. The business's 50 day moving average price is $262.94 and its 200 day moving average price is $269.49. The stock has a market cap of $28.65 billion, a PE ratio of 23.86, a P/E/G ratio of 2.05 and a beta of 0.49. Humana Inc. has a 1-year low of $212.45 and a 1-year high of $406.46.

Humana (NYSE:HUM - Get Free Report) last released its earnings results on Wednesday, April 30th. The insurance provider reported $11.58 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $10.07 by $1.51. The business had revenue of $32.11 billion for the quarter, compared to the consensus estimate of $32 billion. Humana had a return on equity of 11.70% and a net margin of 1.02%. Humana's quarterly revenue was up 8.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $7.23 earnings per share. Research analysts forecast that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be given a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a yield of 1.49%. The ex-dividend date is Friday, June 27th. Humana's dividend payout ratio (DPR) is presently 25.04%.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.